Finding 496771 (2023-005)

Material Weakness
Requirement
B
Questioned Costs
$1
Year
2023
Accepted
2024-09-13
Audit: 319539
Organization: Overdose Lifeline, Inc. (IN)
Auditor: Pile CPAS

AI Summary

  • Core Issue: Grant funds were misallocated, violating terms by using supplies from one federal grant for another.
  • Impacted Requirements: Noncompliance with the Uniform Guidance on allowable costs and proper allocation of federal funds.
  • Recommended Follow-Up: Enhance internal controls, improve communication between departments, and provide staff training on grant management to prevent future issues.

Finding Text

Finding 2023-005 Misallocation of Grant Funds Type of Finding: Noncompliance and Material Weakness in Internal Control over Compliance. Criteria: The Uniform Guidance establishes criteria for allowable costs and the proper use of federal funds. According to Uniform Guidance, costs must be necessary and reasonable for the performance of the federal award and allocated correctly. Additionally, costs must be charged to the federal award based on the benefits received. Condition: The Organization claimed purchases under a reimbursement-based federal grant but then used these supplies for a different grant. This improper use of grant-funded supplies is a violation of the grant’s terms and conditions. Cause: The root cause of the noncompliance is the Organization’s failure to implement effective internal controls to ensure proper communication between departments. While the Organization was aware of the grant terms prohibiting such actions, the lack of controls and processes to coordinate the use of grant-funded supplies resulted in their misallocation. Possible or Known Effect: The misuse of resources risks undermining the programmatic impact intended by the grant. By not using the supplies as specified in the grant agreement, the Organization may fail to achieve the grant’s objectives and intended outcomes, ultimately diminishing the effectiveness of the funded program. Questioned Costs: The total questioned costs amount to $85,178, reflecting the value of supplies used improperly. Repeat Finding: This finding is not a repeat finding from the prior year. Recommendation: To address the identified issue, it is crucial the Organization implement and enhance internal controls and communication processes between departments to ensure compliance with grant requirements. The Organization should implement enhancements in the tracking of supplies by grant. Additionally, the Organization should establish effective oversight mechanisms and provide training to staff on proper grant management practices. A review and revision of grant management policies are necessary to prevent similar issues in the future. Views of Responsible Officials: The Organizations’ Board and Executive Team consisting of the Chief Executive Officer (CEO) and the Chief Operating Officer (COO) and key Overdose Lifeline (ODL) Staff to include the independent bookkeeper and Grant and Finance Manager recognize the need to further significantly improve on the oversight and reconciliation of supply ordering and inventory. This is already underway with the QB inventory process described previously and an improved process for backup documentation. Additionally key staff will complete of a formal course that covers performing a single audit and engage in consultation with the Independent Public Accounting Firm (Pile CPAs).

Corrective Action Plan

Finding 2022-05 Misallocation of Grant Funds Condition: The Organization claimed purchases under a reimbursement-based federal grant but then used these supplies for a different grant. This improper use of grant-funded supplies is a violation of the grant’s terms and conditions. Corrective Actions Taken or Planned: The Organizations’ Board and Executive Team consisting of the Chief Executive Officer (CEO) and the Chief Operating Officer (COO) and key Overdose Lifeline (ODL) Staff to include the independent bookkeeper and Grant and Finance Manager recognize the need to further significantly improve on the oversight and reconciliation of supply ordering and inventory. This is already underway with the QB inventory process described previously and an improved process for backup documentation. Additionally key staff will complete of a formal course that covers performing a single audit and engage in consultation with the Independent Public Accounting Firm (Pile CPAs)

Categories

Questioned Costs Allowable Costs / Cost Principles Internal Control / Segregation of Duties Procurement, Suspension & Debarment Cash Management Material Weakness Equipment & Real Property Management

Other Findings in this Audit

  • 496767 2023-001
    Material Weakness
  • 496768 2023-002
    Significant Deficiency Repeat
  • 496769 2023-004
    Significant Deficiency
  • 496770 2023-003
    Significant Deficiency Repeat
  • 496772 2023-001
    Material Weakness
  • 496773 2023-002
    Significant Deficiency Repeat
  • 496774 2023-004
    Significant Deficiency
  • 496775 2023-003
    Significant Deficiency Repeat
  • 496776 2023-001
    Material Weakness
  • 496777 2023-002
    Significant Deficiency Repeat
  • 496778 2023-004
    Significant Deficiency
  • 496779 2023-001
    Material Weakness
  • 496780 2023-002
    Significant Deficiency Repeat
  • 496781 2023-004
    Significant Deficiency
  • 496782 2023-001
    Material Weakness
  • 496783 2023-002
    Significant Deficiency Repeat
  • 496784 2023-004
    Significant Deficiency
  • 496785 2023-001
    Material Weakness
  • 496786 2023-002
    Significant Deficiency Repeat
  • 496787 2023-004
    Significant Deficiency
  • 496788 2023-001
    Material Weakness
  • 496789 2023-002
    Significant Deficiency Repeat
  • 496790 2023-004
    Significant Deficiency
  • 496791 2023-001
    Material Weakness
  • 496792 2023-002
    Significant Deficiency Repeat
  • 496793 2023-004
    Significant Deficiency
  • 496794 2023-001
    Material Weakness
  • 496795 2023-002
    Significant Deficiency Repeat
  • 496796 2023-004
    Significant Deficiency
  • 1073209 2023-001
    Material Weakness
  • 1073210 2023-002
    Significant Deficiency Repeat
  • 1073211 2023-004
    Significant Deficiency
  • 1073212 2023-003
    Significant Deficiency Repeat
  • 1073213 2023-005
    Material Weakness
  • 1073214 2023-001
    Material Weakness
  • 1073215 2023-002
    Significant Deficiency Repeat
  • 1073216 2023-004
    Significant Deficiency
  • 1073217 2023-003
    Significant Deficiency Repeat
  • 1073218 2023-001
    Material Weakness
  • 1073219 2023-002
    Significant Deficiency Repeat
  • 1073220 2023-004
    Significant Deficiency
  • 1073221 2023-001
    Material Weakness
  • 1073222 2023-002
    Significant Deficiency Repeat
  • 1073223 2023-004
    Significant Deficiency
  • 1073224 2023-001
    Material Weakness
  • 1073225 2023-002
    Significant Deficiency Repeat
  • 1073226 2023-004
    Significant Deficiency
  • 1073227 2023-001
    Material Weakness
  • 1073228 2023-002
    Significant Deficiency Repeat
  • 1073229 2023-004
    Significant Deficiency
  • 1073230 2023-001
    Material Weakness
  • 1073231 2023-002
    Significant Deficiency Repeat
  • 1073232 2023-004
    Significant Deficiency
  • 1073233 2023-001
    Material Weakness
  • 1073234 2023-002
    Significant Deficiency Repeat
  • 1073235 2023-004
    Significant Deficiency
  • 1073236 2023-001
    Material Weakness
  • 1073237 2023-002
    Significant Deficiency Repeat
  • 1073238 2023-004
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.137 Community Programs to Improve Minority Health Grant Program $56,493
93.788 Opioid Str $19,750
21.027 Coronavirus State and Local Fiscal Recovery Funds $18,541